CAS: 154-68-7 - Antazoline phosphate
Formel:C17H19N3·H3O4P
InChl:InChI=1S/C17H19N3.H3O4P/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h1-10H,11-14H2,(H,18,19);(H3,1,2,3,4)
InChI Key:InChIKey=DUIGUKRYYAGJAF-UHFFFAOYSA-N
SMILES:O=P(O)(O)O.N1=C(NCC1)CN(C=2C=CC=CC2)CC=3C=CC=CC3
- Synonyme:
- 1H-Imidazole-2-methanamine, 4,5-dihydro-N-phenyl-N-(phenylmethyl)-, phosphate (1:1)
- 2-((N-Benzylanilino)methyl)-2-imidazoline phosphate (1:1)
- 2-Imidazoline, 2-[(N-benzylanilino)methyl]-, phosphate (1:1)
- 2-[(N-Benzylanilino)methyl]-2-imidazoline dihydrogen phosphate
- Antistine phosphate
- N-Benzyl-4,5-dihydro-N-phenyl-1H-imidazole-2-methylamine monophosphate
- N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
- N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline phosphate (1:1)
- Unii-Vpr5Fph326
- Vasocon-A
- Mehr Synonyme anzeigen
- Antazoline phosphate
Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
---|---|---|---|---|
Antazoline Phosphate REF: 45-1038003CAS: 154-68-7 | - - - | 463,00 € | Di 07 Jan 25 | |
Antazoline phosphate REF: TM-T21020CAS: 154-68-7 | 98% | 1.287,00 € | Di 07 Jan 25 | |
Antazoline Phosphate REF: 86-MM0561.00CAS: 154-68-7 | - - - | 303,00 € | Mi 08 Jan 25 | |
Antazoline Phosphate REF: TR-A678410CAS: 154-68-7 | - - - | 168,00 €~241,00 € | Di 18 Feb 25 | |
Antazoline phosphate REF: 3D-FA46801CAS: 154-68-7 | Min. 95% | Nachfragen | Di 18 Feb 25 | |
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline hydrochloride REF: 10-F391766CAS: 154-68-7 | 95.0% | - - - | Ausgelaufenes produkt |
Antazoline Phosphate
Antazoline phosphate
Ref: TM-T21020
500mg | 1.287,00 € |
Antazoline Phosphate
Kontrolliertes ProduktRef: 86-MM0561.00
500mg | 303,00 € |
Antazoline Phosphate
Kontrolliertes ProduktRef: TR-A678410
1g | 168,00 € | ||
10g | 241,00 € |
Antazoline phosphate
Ref: 3D-FA46801
10kg | Nachfragen | ||
200mg | Nachfragen |
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline hydrochloride
Ref: 10-F391766
25g | Ausgelaufen | Anforderung von Informationen |